Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value
| Autor: | Ana Garrido, Jorge Sierra, Marta Pratcorona, Maite Carricondo, Rodrigo Martino, Salut Brunet, Albert Esquirol, Josep F. Nomdedeu, Miguel Ángel Rubio, Montserrat Hoyos, Elena Bussaglia, Irene García-Cadenas, Camino Estivill |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Myeloid Neoplasm Residual Time Factors Adolescent medicine.medical_treatment Hematopoietic stem cell transplantation 03 medical and health sciences Myelogenous Young Adult 0302 clinical medicine Bone Marrow Internal medicine hemic and lymphatic diseases medicine Molecular diagnostics Humans Transplantation Homologous Cumulative incidence Remission status WT1 Proteins Transplantation Chemotherapy Leukemia business.industry Minimal residual disease Hematopoietic Stem Cell Transplantation Hematology Middle Aged medicine.disease Flow Cytometry Prognosis Survival Analysis WT1 Leukemia Myeloid Acute medicine.anatomical_structure 030220 oncology & carcinogenesis Myelodysplastic Syndromes Immunology Female Bone marrow business 030215 immunology |
| Zdroj: | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Biology of Blood and Marrow Transplantation r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol |
| ISSN: | 1083-8791 |
| Popis: | The outcome of allogeneic hematopoietic stem cell transplantation (HCT) in patients with myeloid malignancies is better in those without minimal residual disease (MRD) than in those with MRD+, as assessed by multiparametric flow cytometry (MPFC). WT1 quantitation also has been used to assess the probability of relapse in acute myelogenous leukemia (AML) treated with chemotherapy. We analyzed the clinical value of normalized bone marrow WT1 levels as a measure of the expanded myeloid progenitor compartment in a consecutive series of 193 adult patients with myeloid malignancies who underwent HCT. Bone marrow WT1 levels before the HCT, at the first bone marrow aspirate after infusion, and in the follow-up samples after HCT were determined by means of real-time PCR using the European LeukemiaNet normalized method. We sought to clarify the prognostic relevance in terms of overall survival (OS), progression-free survival (PFS), and cumulative incidence of relapse (CIR). Based on earlier experience in AML, we selected a threshold of 100 copies, defining 2 groups: patients with 100 copies also included patients who were negative for MRD as assessed by MPFC (19 of 32). During the HCT follow-up, patients with sustained WT1 levels 100 copies (mean, 68 +/- 11 versus 26 +/- 7 days, P < .001; 63 +/- 11 versus 20 +/- 8 days, P < .001; and 20 +/- 8 vs. 71 +/- 8 days, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect